Access Statistics for Izabela Jelovac

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Basic, applied research, and price negotiation for new drugs 0 0 0 0 0 0 7 24
Comparing Organizational Structures in Health Services 0 0 0 0 0 0 12 2,406
Comparing approval procedures for new drugs 0 0 0 0 0 1 14 38
Comparing organizational structures in health services 0 0 0 0 0 1 7 10
Demand versus Supply Side Cost-Sharing: Patients’ preferences 0 0 0 0 0 0 5 24
Demand versus Supply Side Cost-Sharing: The users' perspective 0 0 0 0 0 0 3 24
Demand versus Supply Side Cost-Sharing: The users' perspective 0 0 0 0 0 1 10 27
Des « Nobels » de sciences économiques au service des systèmes de santé 0 0 0 0 0 1 3 17
Des « Nobels » de sciences économiques au service des systèmes de santé 0 0 0 0 0 0 11 11
Do free-of-charge public health services impede cost recovery policies in Khartoum state, Sudan? 0 0 1 8 0 0 9 101
Drug approval decision times, international reference pricing and access to new drugs 0 0 0 0 0 1 18 41
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 6 40
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 11 0 0 6 63
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 1 9 42
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 1 9 43
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 1 11 0 1 18 79
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 1 2 38
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 0 9 47
Drug approval decision times, international reference pricing and strategic launches of new drugs 0 0 0 0 0 1 7 35
Drug launch timing and international reference pricing 0 0 0 17 1 1 10 99
Drug launch timing and international reference pricing 0 0 0 0 0 0 3 28
Drug launch timing and international reference pricing 0 0 0 0 0 0 4 56
Drug launch timing and international reference pricing 0 0 0 0 0 0 3 24
Drug launch timing and international reference pricing 0 0 1 36 0 0 13 80
Drug launch timing and international reference pricing 0 0 0 0 0 0 4 26
Drug launch timing and international reference pricing 0 0 0 0 0 0 3 49
Enjeux tarifaires de la médecine génomique 0 0 0 0 0 2 4 22
External Reference Pricing and Sequential Launching of Drugs 0 0 0 0 0 0 7 42
External referencing and pharmaceutical price negotiation 0 0 0 0 0 0 8 36
External referencing and pharmaceutical price negotiation 0 0 0 10 0 3 12 51
External referencing and pharmaceutical price negotiation 0 0 0 152 0 1 14 473
GPs’ payment contracts and their referral practice 0 0 0 0 0 1 12 14
Generic entry, price competition, and market segmentation in the prescription drug market – A comment 0 0 7 7 0 0 16 16
Generic entry, price competition, and market segmentation in the prescription drug market-A comment 0 0 0 0 0 1 12 12
Health Services: Incentives and Access. Keynote speech 0 0 0 0 0 0 8 28
Health services: Incentives and access 0 0 0 0 0 1 6 25
Healthcare providers’ payments with personalized medicine 0 0 0 0 0 0 7 16
Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality 0 0 0 1 0 0 10 14
How Should Donors Give Foreign Aid? Project Aidversus Budget Support 0 0 0 63 0 1 9 384
How should donors give foreign aid ? A theoretical comparison of aid modalities 0 0 0 0 0 0 4 22
How should donors give foreign aid? Project aid versus budget support 0 0 1 172 0 6 31 681
How should donors give foreign aid? Project aid versus budget support 0 0 0 111 0 0 7 284
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 17 0 0 6 47
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 0 0 1 5 32
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 0 0 1 4 38
Incentives to patients versus incentives to health care providers: The users’ perspective 0 0 0 27 0 0 10 71
La Médecine personnalisée 0 0 0 0 0 0 7 39
Médecine personnalisée et prix des médicaments 0 0 0 0 0 0 2 25
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment 0 0 0 0 0 0 2 67
On the relationship between the negociated price of pharmaceuticals and the patients' co-payment 0 0 0 0 0 1 9 45
Payment mechanism and GP self-selection: capitation versus fee for service 0 0 0 0 0 0 11 65
Perception du lien entre mode de rémunération et comportement des médecins 0 0 0 0 0 0 6 34
Perception du lien entre mode de rémunération et comportement des médecins 0 0 0 0 0 1 5 35
Personalized medicine and drug prices 0 0 0 0 0 0 15 58
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 2 43
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 1 4 48
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 4 50
Physicians Balance Billing, Supplemental Insurance and Access to Health Care 0 0 0 0 0 0 6 35
Physicians self selection of a payment mechanism: Capitation versus fee-for-service 0 0 0 31 0 1 6 95
Physicians self selection of a payment mechanism: Capitation versus fee-for-service 0 0 0 30 0 0 11 303
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 8 22
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 7 21
Physicians' Balance Billing, Fees Negotiations and Supplementary Insurance 0 0 0 0 0 0 22 35
Physicians' balance billing, supplemental insurance and access to health care 0 0 0 16 0 0 4 94
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 27 0 0 4 118
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 0 0 0 6 60
Preferences for Demand versus Supply Side Cost-Sharing 0 0 0 0 0 0 9 22
Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry 0 0 0 3 0 0 11 20
Pricing and Welfare of Parallel Imports in the Pharmaceutical Industry 0 0 0 165 0 0 14 457
Primary Care, Gatekeeping and Incentives 0 0 0 0 0 1 11 105
Regulation and Altruism 0 0 0 25 0 0 14 49
Regulation and Altruism 0 0 0 29 1 1 9 57
Regulation and altruism 0 0 0 27 0 0 7 47
Regulation and altruism 0 0 0 9 0 2 13 50
Research funding and price negotiation for new drugs 0 0 0 55 0 0 9 54
Research funding and price negotiation for new drugs 0 0 0 47 0 1 11 33
Research funding and price negotiation for new drugs 0 0 0 0 0 1 10 14
Research funding and price negotiation for new drugs 0 0 0 0 0 0 6 24
Research funding and price negotiation for new drugs 0 0 0 0 1 1 8 14
Research funding and price negotiation for new drugs 0 0 0 0 0 0 4 12
Research funding and price negotiation for new drugs 0 0 0 0 0 0 5 15
Research funding and price negotiation for new drugs 0 0 0 0 0 1 9 28
The pricing of physicians' services with distant medicine and health insurance 0 0 1 8 0 0 6 16
The pricing of physicians' services with distant medicine and health insurance 0 0 0 8 0 0 17 45
Treatment and referral decisions under different physician payment mechanisms 0 0 0 39 0 0 12 118
Total Working Papers 0 0 12 1,162 3 41 723 8,252
1 registered items for which data could not be found

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Comparing approval procedures for new drugs 0 0 1 10 0 0 9 37
Comparing organizational structures in health services 0 0 0 125 0 0 9 374
Drug Launch Timing and International Reference Pricing 0 0 0 11 0 2 19 58
External referencing and pharmaceutical price negotiation 0 0 0 40 0 0 11 191
GPs' payment contracts and their referral practice 0 0 0 85 0 1 14 312
Generic entry, price competition, and market segmentation in the prescription drug market – a comment 0 0 0 0 2 2 8 8
Household health-seeking behaviour in Khartoum, Sudan: The willingness to pay for public health services if these services are of good quality 0 0 0 34 0 0 13 147
How Should Donors Give Foreign Aid? A Theoretical Comparison of Aid Modalities 0 0 1 17 1 1 17 54
Incentives to patients versus incentives to health care providers: The users' perspective 0 0 0 6 0 0 8 33
On the relationship between the negotiated prices of pharmaceuticals and the patients' co-payment 0 0 0 41 1 1 16 143
Payment mechanism and GP self-selection: capitation versus fee for service 0 0 0 20 0 1 12 233
Physicians' payment contracts, treatment decisions and diagnosis accuracy 0 0 0 3 0 0 7 204
Physicians’ balance billing, supplemental insurance and access to health care 0 0 0 12 0 1 8 74
Pricing and Welfare Implications of Parallel Imports in the Pharmaceutical Industry 0 0 0 129 0 0 12 344
Regulation and altruism 0 0 0 0 0 0 9 28
Research funding and price negotiation for new drugs 0 0 0 4 0 0 12 47
Treatment and referral decisions under different physician payment mechanisms 0 0 0 19 0 1 14 126
Total Journal Articles 0 0 2 556 4 10 198 2,413

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-08-07